Feedback / Questions
rondecabtagene autoleucel (LYL314) - Lyell Immunopharma
https://www.globenewswire.com/news-release/2025/06/17/3100483/0/en/Lyell-Immunopharma-Announces-Positive-New-Clinical-Data-Demonstrating-High-Rates-of-Durable-Complete-Responses-from-the-Phase-1-2-Trial-of-LYL314-for-the-Treatment-of-Aggressive-La.html
Jun 17, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next